Zydus Lifesciences has achieved a major regulatory milestone with the USFDA accepting its BLA for FYB206, a proposed biosimilar to Merck’s blockbuster drug Keytruda. Partnered with Formycon AG, Zydus holds exclusive North American commercialization rights. A final decision is anticipated by Q3 2027, marking a pivotal step in the company's oncology expansion strategy.
Zydus Lifesciences Advances Oncology Pipeline with USFDA BLA Acceptance
The USFDA has officially accepted for review the Biologics License Application (BLA) for Zydus Lifesciences’ FYB206.
The regulatory decision for this Keytruda biosimilar is currently targeted for the third quarter of 2027.
Reader Takeaway: Zydus secures critical entry into the multibillion-dollar oncology market, though commercial success depends on future regulatory clearance.
What just happened
Zydus Lifesciences announced that the USFDA has accepted its Biologics License Application for FYB206, a proposed biosimilar to the oncology drug Keytruda (pembrolizumab). This filing, submitted in Q3 2026, is noted as the first of its kind for a Keytruda biosimilar to reach this stage of regulatory review. The company has also initiated the filing process with Health Canada.
Why this matters
Keytruda is a high-demand immune checkpoint inhibitor, with global sales for the reference product and its variants reaching USD 31.7 billion in 2025. By entering this space, Zydus positions itself to capture a share of this significant market. The development pathway was streamlined after reaching an agreement with the USFDA in early 2025, which waived the requirement for a comparative Phase III efficacy trial.
The strategic partnership
In December 2025, Zydus entered into an exclusive licensing and supply agreement with Formycon AG for the US and Canadian markets. Formycon manages development, regulatory filings, and manufacturing, while Zydus oversees commercialization. The recent USFDA acceptance has triggered a milestone payment from Zydus to Formycon, underscoring the collaborative nature of this initiative.
Risks to watch
While BLA acceptance is a positive indicator, the pathway to market remains subject to final regulatory approval. Furthermore, as with all biosimilars of high-value biologics, the company faces potential challenges regarding intellectual property and patent litigation that may affect market entry timing.
What to track next
Investors should monitor the ongoing review process under the Biosimilar User Fee Amendments (BsUFA) guidelines, as well as any updates regarding the Canadian submission. The company is expected to provide periodic updates as it approaches the projected Q3 2027 decision window.